Market revenue in 2021 | USD 40.9 million |
Market revenue in 2030 | USD 242.2 million |
Growth rate | 21.9% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 33.25% in 2021. Horizon Databook has segmented the Latin America non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
The rise in the number of private-public partnerships to promote research on biomarkers is expected to drive the Latin America non-alcoholic steatohepatitis biomarkers market. The Latin American Drug-Induced Liver Injury (DILI) Registry is an ongoing strategic collaboration of Latin American countries for studying genetic biomarkers by collecting biological samples.
Diabetes and obesity are common in the Latin American population. This can be attributed to the rapid increase in the consumption of fat-rich food by individuals, a habit observed in most developing economies. Hence, the risk of NASH is high in this region.
This is expected to propel the demand for biomarkers for diagnosis, prognosis, and treatment of NASH. However, the lack of healthcare in underdeveloped regions leads to high number of underdiagnosed cases.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account